{rfName}
As

Indexed in

License and Use

Icono OpenAccess

Citations

3

Altmetrics

Analysis of institutional authors

Torrado, AngelAuthor

Share

October 15, 2024
Publications
>
Article
Sí

Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis

Publicated to: International Journal Of Molecular Sciences. 25 (18): 10012- - 2024-09-01 25(18), DOI: 10.3390/ijms251810012

Authors: Domínguez-Mozo, MI; Casanova, I; Monreal, E; Costa-Frossard, L; Sainz-de-la-Maza, S; Sainz-Amo, R; Aladro-Benito, Y; Lopez-Ruiz, P; De-Torres, L; Abellán, S; Garcia-Martinez, MA; De-la-Cuesta, D; Lourido, D; Torrado-Carvajal, A; Gomez-Barbosa, C; Linares-Villavicencio, C; Villar, LM; López-De-Silanes, C; Arroyo, R; Alvarez-Lafuente, R

Affiliations

Hosp Univ Getafe, Dept Neurol, Madrid 28905, Spain - Author
Hosp Univ QuironSalud Madrid, Dept Neurol, Madrid 28223, Spain - Author
Hosp Univ Torrejon, Dept Neurol, Madrid 28850, Spain - Author
Hosp Univ Torrejon, Dept Radiol, Madrid 28850, Spain - Author
Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Res Grp Environm Factors Neurodegenerat Dis, Red Enfermedades Inflamatorias REI, Madrid 28040, Spain - Author
Univ Alcala, Hosp Univ Ramon & Cajal, Dept Immunol, Red Enfermedades Inflamatorias REI,Inst Ramon & Ca, Madrid 28034, Spain - Author
Univ Alcala, Hosp Univ Ramon & Cajal, Dept Neurol, Red Enfermedades Inflamatorias REI,Inst Ramon & Ca, Madrid 28034, Spain - Author
Univ Alcala, Hosp Univ Ramon & Cajal, Dept Radiol, Inst Ramon & Cajal Invest Sanitaria, Madrid 28034, Spain - Author
Univ Francisco Vitoria, Sch Med, Madrid 28223, Spain - Author
Univ Rey Juan Carlos, Med Image Anal & Biometry Lab, Madrid 28850, Spain - Author
See more

Abstract

microRNAs (miRNAs) are promising biomarkers for many diseases, including multiple sclerosis (MS). The neurofilament light chain (NfL) is a biomarker that can detect axonal damage in different neurological diseases. The objective of this study was to evaluate the association of the expression profile of pre-selected miRNAs and NfL levels with clinical and radiological variables in MS patients. We conducted a 1-year longitudinal prospective study in MS patients with different clinical forms. We measured clinical disability using the expanded disability status scale (EDSS), the magnetic resonance imaging (MRI) volumetry baseline, and cognitive functioning using the processing speed test (PST) at baseline and 1 year later. Selected serum miRNAs and serum NfL (sNfL) levels were quantified. Seventy-three patients were recruited. MiR-126.3p correlated with EDSS and cognitive status at baseline and miR-126.3p and miR-9p correlated with cognitive deterioration at 1 year. Correlations with regional brain volumes were observed between miR-126.3p and the cortical gray matter, cerebellum, putamen, and pallidum; miR-146a.5p with the cerebellum and pallidum; miR-29b.3p with white matter and the pallidum; miR-138.5p with the pallidum; and miR-9.5p with the thalamus. sNfL was correlated with miR-9.5p. miR-146a.5p was also associated with the MS phenotype. These data justify future studies to further explore the utility of miRNAs (mirR-126.3p, miR-146.5p, and miR.9-5p) and sNfL levels as biomarkers of MS.

Keywords

AdultBiomarkersBrainCellsFemaleHumansLongitudinal studiesMagnetic resonance imagingMagnetic resonance imaging (mri)MaleMicrornasMicrornas (mirnas)Middle agedMir-126ModeMultiple sclerosisNeurofilament light (nfl)Neurofilament protein lNeurofilament proteinsProcessing speed test (pstProcessing speed test (pst)ProgressionProspective studiesRelapse

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal International Journal Of Molecular Sciences due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 72/319, thus managing to position itself as a Q1 (Primer Cuartil), in the category Biochemistry & Molecular Biology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-12-15:

  • WoS: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-12-15:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 15.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 15 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 2.
  • The number of mentions on the social network X (formerly Twitter): 2 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Awards linked to the item

This research was funded by the Ministry of Science and Innovation (Knowledge generation projects) European Regional Development Fund (ERDF) (PID2021-126041OB-I00), LAIR Foundation, and Mutua Madrilena Foundation.